Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer

American Journal of Cancer Research

Volumn 5, Issue 1, 2015, Pages 375-385

  Murria, Rosa ^a   Palanca, Sarai ^a   De Juan, Inmaculada ^a   Egoavil, Cecilia ^b   Alenda, Cristina ^b   García Casado, Zaida ^c   Juan, María J ^c   Sánchez, Ana B ^d   Santaballa, Ana ^a   Chirivella, Isabel ^e   Segura, ángel ^a   Hervás, David ^f   Llop, Marta ^a   Barragán, Eva ^a   Bolufer, Pascual ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b University General Hospital   (Spain)

^c IVO   (Spain)

^d Allergy Service   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HEALTH RESEARCH INSTITUTE LA FE   (Spain)

Author keywords

Breast cancer; Copy number aberrations; Immunochemistry; Promoter methylation

Indexed keywords

ATM PROTEIN; AURORA A KINASE; CASPASE 8; CELL CYCLE PROTEIN 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE P1; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROGESTERONE RECEPTOR; PROTEIN P53; UVOMORULIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; ATM GENE; AURKA GENE; BREAST CANCER; CASP8 GENE; CDC6 GENE; CDKN2A GENE; CDKN2B GENE; CHFR GENE; CONTROLLED STUDY; COPY NUMBER ABERRATION; DAPK1 GENE; DNA METHYLATION; GENE; GENE MUTATION; GSTP1 GENE; HUMAN; HUMAN TISSUE; MAPT GENE; MED1 GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRMD14 GENE; PROMOTER REGION; PROTEIN EXPRESSION; RASSF1 GENE; TUMOR SUPPRESSOR GENE; VHL GENE;

EID: 84943757784     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 13-18.
2. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg A, Ringnér M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010; 12: R36.
3. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
4. Jovanovic J, Rønneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol 2010; 4: 242-254.
5. Roa JC, Anabalón L, Tapia O, Martínez J, Araya JC, Villaseca M, Guzmán P, Roa I. Promoter methylation profile in breast cancer. Rev Med Chil 2004; 132: 1069-1077.
6. Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treat 2013; 142: 365-380.
7. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 2009; 28: 2969-2978.
8. Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, Carr JM, Khrebtukova I, Luo S, Zhang L, Schroth GP, Perez EA, Thompson EA. Integrated analysis of gene expression, CPG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One 2011; 6: e17490.
9. Kajabova V, Smolkova B, Zmetakova I, Sebova K, Krivulcik T, Bella V, Kajo K, Machalekova K, Fridrichova I. RASSF1A promoter methylation levels positively correlate with estrogen receptor expression in breast cancer patients. Transl Oncol 2013; 6: 297-304.
10. Rhee JK, Kim K, Chae H, Evans J, Yan P, Zhang BT, Gray J, Spellman P, Huang TH, Nephew KP, Kim S. Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. Nucleic Acids Res 2013; 41: 8464-8474.
11. Xu X, Gammon MD, Zhang Y, Cho YH, Wetmur JG, Bradshaw PT, Garbowski G, Hibshoosh H, Teitelbaum SL, Neugut AI, Santella RM, Chen J. Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2010; 121: 685-692.
12. The cancer genome atlas network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
13. Anders O, Nygren H, Ameziane N, Duarte HMB, Vijzelaar R, Waisfisz Q, Hess CJ, Schouten JP, Errami A. Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005; 33: e128.
14. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, Errami A, Schouten JP, Meijer CJ, Snijders PJ, Steenbergen RD. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Brit J Cancer 2007; 97: 1457-1464.
15. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57
16. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ. Molecular profiling of invasive breast cancer by multiplex ligation dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 2010; 23: 1029-1039.
17. Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, Duncan PJ, Curtis CE, Robinson DO, Harvey JF, Cross NC. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 2004; 91: 1155-1159.
18. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: e48-72.
19. Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 2008; 8: 417-434.
20. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
21. Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F, Wang D, Chen W, Huang O, Chen X, Wu J, Shen K, Loo WT, Chow LW. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med 2012; 10: S4.
22. Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma. J Pathol 2001; 193: 433-441.
23. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
24. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
25. Ward JH. Hierarchical Grouping to Optimize an Objective Function. J Am Statist Assoc 1963; 58: 236-244.
26. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65-70.
27. Tibshirani R. Regression shrinkage and selection via the lasso. J R Statist Soc B 1996; 58: 267-288.
28. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004; 10: 5349-5354.
29. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005; 11: 2156-2162.
30. Purnomosari D. Molecular analysis of early onset Indonesian breast cancer. Doctoral Thesis. 2006. The Netherlands: Utrecht University.
31. Brooks J, Cairns P, Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Cause Control 2009; 20: 1539-1550.
32. Zhang W, Yu Y. The important molecular markers on chromosome 17 and their clinical impact in breast cancer. Int J Mol Sci 2011; 12: 5672-5683.
33. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene 2006; 25: 5906-5911.
34. Wang L, Tang L, Xie R, Nie W, Chen L, Guan X. P16 promoter hypermethylation is associated with increased breast cancer risk. Mol Med Rep 2012; 6: 904-908.
35. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.
36. Erson AE, Petty EM. CHFR-associated early G2/M checkpoint defects in breast cancer cells. Mol Carcinog 2004; 39: 26-33.
37. Privette LM, González ME, Ding L, Kleer CG, Petty EM. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res 2007; 67: 6064-6074.
38. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Ltehner D, Bircluneier W. E-Cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-185.
39. Luoh SW. Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. Cancer Genet Cytogenet 2002; 136: 43-47.
40. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005; 102: 8315-8320.
41. Fu J, Biang M, Jiang Q, Zhang C. Roles of Aurka kinases in mitosis and tumorigenesis. Mol Cancer Res 2007; 5: 1-10.
42. Bolardo L, Méndez J. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 2008; 29: 237-243.
43. Nishikawa N, Toyota M, Suzuki H, Honma T, Fujikane T, Ohmura T, Nishidate T, Ohe-Toyota, Maruyama R, Sonoda T, Sasaki Y, Urano T, Imai K, Hirata K, Tokino T. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 2007; 67: 9649-9657.
44. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. PNAS 1997; 94: 2545-2550.
45. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58: 4515-4518.
46. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007; 16: R50-R59.
47. Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer 2010; 10: 32.
48. Saxena A, Dhillon VS, Shahid M, Khalil HS, Rani M, Prasad DAS T, Hedau S, Hussain A, Naqvi RA, Deo SV, Shukla NK, Das BC, Husain SA. GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients. Exp Ther Med 2012; 4: 1097-1103.
49. Levy-Strumpf N, Kimchi A. Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene 1998; 17: 3331-3340.
50. Shivakumar L, Minna J, Sakamaki J, Pestell R, White M. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002; 22: 4309-4318.
51. Dammann R, Li C, Yoon J, Chin P, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-319.